Table 1 Study characteristics
Study | Participants Number | Dialysis modality HD, PD | Median Age HD, PD | Ethnicity/Race | Follow-up time HD; PD | Primary study aim | Country of study | Outcome measure |
|---|---|---|---|---|---|---|---|---|
Kang 2011 [13] | 59 | 28, 14 | 35, 41 | Not Reported | 5 ± 3; 5 ± 3 (Years) | Long-term outcome of patients with ESRD secondary to SLE who are managed by different types of RRTs | South Korea | LFR, IR, MR, PS |
Tsai 2019 [19] | 94 | 42, 12 | 36.40, 33.20 | Not Reported | 6.30 ± 5.10; 6.00 ± 5.20 (Years) | Long-term outcomes and survival rates of patients with ESRD caused by lupus nephritis who received 3 different modalities of renal replacement therapy | Taiwan | LFR, IR, MR, CVR, PS |
Krane 1999 [20] | 19 | 7, 5 | 32, 36 | 10 black, 2 Whites | 3 years; 3 years | Lupus activity among patients with ESRD due to SLE, who were either undergoing dialysis or had undergone transplantation | USA | LFR |
Chang 2013 [21] | 1073 | 813, 260 | 42.60, 34.10 | Not reported | ≥ 3 months on RRT; ≥ 3 months on RRT | Mortality and the impact of dialysis modalities on the survival in SLE patients with end-stage renal disease (ESRD). | Taiwan | IR, MR, CVR, PS |
Weng 2009 [22] | 36 | 14, 22 | 48.70, 37.59 | Not reported | 126.83; 37 (Months) | Comparing PD and HD outcomes between female SLE patients with ESRD due to lupus nephropathy | Taiwan | IR, CVR, MR, PS |
Wu 2014 [23] | 1998 | 1640, 196 | 39.30, 36.20 | Not Reported | 3.31 ± 3.87; 4.34 ± 3.05 (Years) | Outcomes of patients with LN after progression to ESRD and to try to elucidate whether deferral of KT is necessary in the Chinese population. | Taiwan | MR, PS |
Contreras 2014 [24] | 11,023 | 1352, 1352 | 39,39 | Caucasian American; African American; Asian Americans; Other Americans. | 3 years; 3 years (Median) | Comparing the mortality risk of ESRD patients with SLE initiating with PD versus HD | USA | MR |
Stock 1993 [31] | 6 | 6, 6 | Not Accessed | Not Accessed | Not Accessed | Determining if there was a difference in disease activity between treatment modalities, using patients as self-controls | USA | LFR |
Zhu 2009 [32] | 29 | 10, 19 | 34.50, 41.79 | Not Reported | 2 years; 2 years | Comparing 2-year outcome of ESRD in lupus nephritis patients in different dialysis modality. | China | LFR, IR, MR, CVR, PS |
Ntatsaki 2018 [16] | 361 | 17, 9 | Not Accessed | Caucasian; Afro–Caribbean; South Asian | 43 (Confidence interval13–49) (Months) | Investigating the time spent on dialysis before RT and survival ollowing RT in a cohort of SLE patients. | UK | MR |
Zhang 2016 [33] | 425 | 314, 111 | Not Accessed | European; Maori and Pacific Islanders; Asian; Others | 3.80 Years (Median); 3.80 Years (Median) | Comparing dialysis and transplant outcomes for patients with ESRD due to lupus nephritis to all other causes | Australia | MR |
Levy 2015 [34] | 368 | 308, 60 | 43.50, 43.90 | Not Reported | 5 Years; 5 Years | Describing the outcomes of SLE on chronic dialysis | France | MR, CVR |
Mustapic 2013 [35] | 7 | 6, 1 | Not Accessed | Not Reported | Up to 10 years | Evaluating outcomes of pediatric patients with ESRD due to lupus nephritis and to determine has intensive specific treatment in SLE decreased incidence of ESRD and need for RRT, dialysis and kidney transplantation, in pediatric patients in the last 4 decades in Croatia | Croatia | MR |
Kang 2010 [36] | 59 | 28, 14 | Not Accessed |  | 5 ± 3 Years; 5 ± 3 Years; | Demonstrating the long-term outcome of lupus patients that underwent different RRTs including kidney transplantation | South Korea | LFR, CVR |
Oliveira 2012 [37] | 50 | 11, 2 | Not Accessed | Non-Caucasians | 11 Months;30 Months | Determining the epidemiological profile and outcome of patients with LN undergoing renal transplantation. | Brazil | LFR, MR |
Lee 2003 [38] | 26 | 20, 6 | Not Accessed | Not recorded | 57.50 ± 4.20 Months | Investigating the long-term prognosis of 26 SLE patients who started regular dialysis at a Chinese hospital whose stay exceeded a 3-month duration. | Taiwan | MR |